Redeye: Initiator Pharma (Q3 review) - Back in the clinic
Idag, 16:03
Redeye provides a research update following the Q3 report recently published by Initiator Pharma. While OPEX has slightly increased as the company initiates clinical activities again, the financials in the report did not contain any major surprises. Instead, the primary focus of the quarter has been on the reignited clinical development of pudafensine – now in the form of a phase IIa study in vulvodynia.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
Redeye: Initiator Pharma (Q3 review) - Back in the clinic
Idag, 16:03
Redeye provides a research update following the Q3 report recently published by Initiator Pharma. While OPEX has slightly increased as the company initiates clinical activities again, the financials in the report did not contain any major surprises. Instead, the primary focus of the quarter has been on the reignited clinical development of pudafensine – now in the form of a phase IIa study in vulvodynia.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
Kinneviks VD slutar
Analyser
-950x950.jpg&w=3840&q=75)
Börsen
USA
Kinneviks VD slutar
Mest läst
Analyser
Börsen
USA
Marknadsöversikt
1 DAG %
Senast
1 mån
